Search

Switzerland: Specialised Polymer Compounds Clariant’s Facilities Certified with New Quality Standard for Plastic Medical Devices

| Editor: Ahlam Rais

The new stringent quality standard ISO 13485-2016 is expected to become mandatory for device manufacturers. The firm has adopted this strategy across three of its sites in USA, Europe and Asia.

Related Companies

Lewiston medical compounding site with ‘all polymer’ capability.
Lewiston medical compounding site with ‘all polymer’ capability.
(Source: Clariant)

Muttenz/Switzerland – Clariant has announced that its recently expanded facility in Lewiston Maine, and two other sites in Malmo, Sweden, and Singapore have been certified to the stringent new quality standard for makers of plastic medical devices.

The plants produce specialised polymer compounds and masterbatches offered for medical applications under the Mevopur brand. After a 3-year transition period during which manufacturers could continue following an earlier version, ISO 13485-2016 goes into full effect at the end of February 2019. Device submissions under the old version will no longer be allowed.

Although ISO 13485 technically only applies to producers of medical devices, it is seen as an important standard for their suppliers, like Clariant, because it helps reduce risks such as risk of changes in raw materials impacting device performance, reliability, or regulatory compliance. Increased use of QbD (Quality by Design) processes means that more consideration needs to be given to materials used and impact on patient safety.

The company began introducing the Mevopur family of products and services more than a decade ago, to help minimise risk at every stage of a medical device’s life cycle. A global team of specialists from R&D, production, sales and marketing, and customer service, works closely with individual customers to pre-test materials and assess risk in order to build compliant, targeted colour and functionality into each application.

The three global facilities, almost entirely dedicated to medical and pharmaceutical applications, provide assurance of consistency in formulations and procedures, and supply-chain reliability for all Mevopur products. Raw materials are pre-tested to standards commonly required for device and drug filings, e.g.: USP <87><88> (‘USP Class VI’) and ISO10993, as well as the USP<661.1>, ICHQ3D and European Pharmacopeia monographs 3.1 covering drug packaging and delivery devices. Segregated storage and manufacturing lines, plus scrupulous change-control processes, reduce the risk of cross contamination.

The desire to comply with the requirements of the new ISO 13485-2016 standard presented additional challenges, however. For example, for the first time, computerised systems needed to be risk-assessed, and then the appropriate validation or verification activities carried out. Even if software is not directly controlling processes, it often present in test equipment used to control raw materials or end-product quality. The project to implement the new version ISO13485-2016 was conducted on a global basis with local site quality managers supported by Clariant’s dedicated Global Quality & Regulatory manager for the healthcare sector.

Lewiston Expansion

Compliance with the new ISO 13485-2016 standard, caps off a multi-million dollar, multi-year expansion programme at the Lewiston, Maine. The facility, which was expanded by 40 %, now accommodates not only extrusion equipment, but also materials handling, weighing stations, a maintenance area and additional water-cooling capacity that enable the Lewiston plant to more rapidly produce larger batch sizes of Mevopur pre-colored medical plastic compounds (e.g.: 3000 to 6000kg /6000 to 12000lbs or larger). A smaller line, installed last year, is configured to meet the rigorous processing requirements of fluoropolymer resins such as, FEP, ETFE, and PVDF.

This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 45723044)